SEP 2 2026
Protagonist Therapeutics — rusfertide $PTGX
for polycythemia vera
Accepted MAR 2 2026.
About
Polycythemia vera is a blood cancer where the bone marrow overproduces red blood cells, thickening the blood and increasing the risk of clots and strokes. Rusfertide is an injectable peptide that mimics the liver hormone hepcidin, which regulates iron availability for red blood cell production. By limiting iron, the drug may reduce excessive red cell counts and help control the symptoms and complications of the disease.
Pivotal trial
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on rusfertide
- Will Icotyde’s Launch and Rusfertide’s Priority Review Change Protagonist Therapeutics’ (PTGX) Narrative - simplywall.st
- Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued - finance.yahoo.com
- Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed? - finance.yahoo.com
- Rusfertide Maintains Long-Term Thromboembolism Control in Phlebotomy-Dependent Polycythemia Vera - OncLive
- Takeda Prepares For Rusfertide, Oveporexton, Zasocitinib Launches - insights.citeline.com
Sponsor Watch — recent news on Protagonist Therapeutics
- Protagonist Therapeutics Reports Granting of Inducement Awards
- Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued
- Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?
- Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress